+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Trogarzo (ibalizumab; Theratechnologies/TaiMed Biologics) Drug Overview 2019

  • ID: 4846161
  • Report
  • 13 pages
  • Datamonitor Healthcare
1 of 2
Drug Overview
Trogarzo (ibalizumab; Theratechnologies/TaiMed Biologics) is a recombinant humanized monoclonal antibody approved for the treatment of HIV-1 infection. It targets the HIV-1 post-attachment process by binding one of the domains of the CD-4 protein, which inhibits a conformational change in CD-4 that is necessary to allow entry of HIV into T-cells.

Trogarzo is the first monoclonal antibody to be approved for the treatment of HIV. Due to fulfilling an unmet need for additional treatments in the small niche of multidrug-resistant patients, Trogarzo has been priced at a significant premium to other therapies, at an annual list price of $118,000 in the US. While Trogarzo possesses a first-to-market advantage and is currently benefiting from a monopoly in multidrug-resistant patients, its inconvenient biweekly intravenous formulation is a key weakness which leronlimab (CytoDyn) (weekly subcutaneous) and fostemsavir (ViiV Healthcare) (oral twice daily) are aiming to exploit. TaiMed Biologics ultimately intends to develop a subcutaneous version of Trogarzo, but this will not be available before the aforementioned competitors’ anticipated US approvals begin to erode its market share. Nevertheless, during the short-lived monopoly period, the author expects Trogarzo will generate substantial sales in the small salvage setting due to its premium price.
Note: Product cover images may vary from those shown
2 of 2
  • Drug Overview
  • Product Profiles
  • Trogarzo: HIV
Figure 1: The author's drug assessment summary of Trogarzo for HIV
Figure 2: The author's drug assessment summary of Trogarzo for HIV
Figure 3: Trogarzo sales for HIV across the US and five major EU markets, by country, 2018–27

Table 1: Trogarzo drug profile
Table 2: Approval history of Trogarzo for HIV in the US
Table 3: Late-phase trials of Trogarzo for HIV
Table 4: Trogarzo for HIV – SWOT analysis
Note: Product cover images may vary from those shown
3 of 2